Navigation Links
ImmunoCellular Therapeutics to Host Conference Call and Webcast to Discuss ICT-107 Program in Newly Diagnosed Glioblastoma on November 24, 2015
Date:11/23/2015

LOS ANGELES, Nov. 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to host a conference call and webcast at 4:30 pm ET on Tuesday, November 24, 2015 to discuss the ICT-107 program in patients with newly diagnosed glioblastoma, including recently reported updated phase 2 clinical trial results and the design of the phase 3 registrational program. The conference call and webcast will be hosted by Andrew Gengos, President and CEO.

 

LIVE CALL:

(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 89218581WEBCAST:

Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient enrollment. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com

Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

 

 


'/>"/>
SOURCE ImmunoCellular Therapeutics, Ltd.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015
2. ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial
3. ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
4. ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
5. ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
6. ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing
7. ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial
8. ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
9. ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th
10. ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015
11. ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2019)... ... July 10, 2019 , ... DidCBDWork.com is the first website aimed ... months, does CBD actually work? It seems like depending on what you read, CBD ... instead aims to get testimonials of real CBD users, who are attempting to ease ...
(Date:7/10/2019)... ... 2019 , ... Successful actor and philanthropist, Laurence Fishburne, is ... of healthcare and how these costs affect American consumers. , The episode addresses ... painful decisions families face between paying for essential health services they require and ...
(Date:7/9/2019)... ... 10, 2019 , ... Women’s Excellence’s goal is treating the ... in-depth interpretation of symptoms, evaluate a women’s lifestyle, and conduct physical examination and ... wants and needs for your menopausal management. Our team specializes in bioidentical ...
Breaking Medicine Technology:
(Date:7/9/2019)... (PRWEB) , ... July 10, 2019 , ... ... to the role of Client Services Manager and will lead the growing team ... new role at First Healthcare Compliance and look forward to further developing new ...
(Date:7/9/2019)... ... 09, 2019 , ... Human cytomegalovirus (HCMV) may not be a household name ... Veterinary Medicine at UMD, half of the population walking around campus is likely to ... of your life and can flare up whenever your immune system is severely compromised, ...
(Date:7/9/2019)... ... July 09, 2019 , ... A2LA is pleased to announce the accreditation ... oils, and solids. GEL Laboratories is based in Charleston, South Carolina, and is the ... first laboratory in the field of environmental testing to expand their scope to include ...
(Date:7/9/2019)... ... July 09, 2019 , ... Anxiety help can often feel out of reach ... A new online therapy platform called Emote seeks to change this for ... through their mobile device, tablet or computer to highly qualified licensed therapists online. Easily ...
(Date:7/9/2019)... ... 09, 2019 , ... Advanced Intelligent Systems (AIS) , ... shortage problems in agriculture, will demonstrate their flagship autonomous custom robot, called ... North America’s leading trade show for the horticulture industry. , “We are ...
Breaking Medicine News(10 mins):